JP2021535149A5 - - Google Patents
Info
- Publication number
- JP2021535149A5 JP2021535149A5 JP2021510824A JP2021510824A JP2021535149A5 JP 2021535149 A5 JP2021535149 A5 JP 2021535149A5 JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021535149 A5 JP2021535149 A5 JP 2021535149A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- seq
- her2 bispecific
- pharmaceutical product
- system inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18191041 | 2018-08-27 | ||
| EP18191041.5 | 2018-08-27 | ||
| PCT/EP2019/072754 WO2020043683A1 (en) | 2018-08-27 | 2019-08-27 | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535149A JP2021535149A (ja) | 2021-12-16 |
| JP2021535149A5 true JP2021535149A5 (https=) | 2022-08-12 |
| JP7459058B2 JP7459058B2 (ja) | 2024-04-01 |
Family
ID=63578931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510824A Active JP7459058B2 (ja) | 2018-08-27 | 2019-08-27 | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210246219A1 (https=) |
| EP (1) | EP3843849A1 (https=) |
| JP (1) | JP7459058B2 (https=) |
| KR (1) | KR20210052468A (https=) |
| CN (1) | CN112955221A (https=) |
| AU (1) | AU2019328632A1 (https=) |
| CA (1) | CA3106881A1 (https=) |
| WO (1) | WO2020043683A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3946417A1 (en) * | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
| KR20220145859A (ko) * | 2020-02-28 | 2022-10-31 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물, 다중 특이적 항체 및 그 용도 |
| JP2023541482A (ja) * | 2020-09-18 | 2023-10-02 | ピエリス ファーマシューティカルズ ゲーエムベーハー | バイオマーカー法および使用法 |
| JP2024504388A (ja) * | 2021-01-25 | 2024-01-31 | ユーハン・コーポレイション | 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法 |
| AU2022241940A1 (en) | 2021-03-23 | 2023-10-26 | Pieris Pharmaceuticals Gmbh | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
| CN118632872A (zh) * | 2022-01-25 | 2024-09-10 | 美勒斯公司 | 用于治疗癌症的组合疗法 |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CA2611861C (en) | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102291355B1 (ko) * | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| MY175472A (en) | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
| EP3060581A4 (en) | 2013-10-25 | 2017-06-07 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| JP2017507900A (ja) * | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| JP6783797B2 (ja) * | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| RU2693661C2 (ru) | 2016-03-04 | 2019-07-03 | Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. | Антитело против pdl-1, его фармацевтическая композиция и применение |
-
2019
- 2019-08-27 US US17/271,149 patent/US20210246219A1/en not_active Abandoned
- 2019-08-27 CA CA3106881A patent/CA3106881A1/en active Pending
- 2019-08-27 CN CN201980071320.7A patent/CN112955221A/zh active Pending
- 2019-08-27 KR KR1020217007565A patent/KR20210052468A/ko not_active Ceased
- 2019-08-27 WO PCT/EP2019/072754 patent/WO2020043683A1/en not_active Ceased
- 2019-08-27 AU AU2019328632A patent/AU2019328632A1/en not_active Abandoned
- 2019-08-27 JP JP2021510824A patent/JP7459058B2/ja active Active
- 2019-08-27 EP EP19756382.8A patent/EP3843849A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535149A5 (https=) | ||
| van de Donk et al. | T-cell-engaging bispecific antibodies in cancer | |
| Poletto et al. | Treatment strategies for patients with diffuse large B-cell lymphoma | |
| Choi et al. | T-cell agonists in cancer immunotherapy | |
| Ferris et al. | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | |
| Vacchelli et al. | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Cultrera et al. | Diffuse large B-cell lymphoma: current strategies and future directions | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2022532490A5 (https=) | ||
| KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
| KR102786010B1 (ko) | 조합 및 이의 용도 | |
| JP2021525735A5 (https=) | ||
| JP2024505556A (ja) | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| JP2023536655A5 (https=) | ||
| JP2024167261A (ja) | 抗原結合タンパク質 | |
| JP7158677B2 (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 | |
| WO2019177011A1 (ja) | 腫瘍免疫賦活剤 | |
| Lam et al. | Pharmacokinetics and pharmacodynamics of immunotherapy | |
| CA3214753A1 (en) | Dosing of bispecific t cell engager | |
| Forero-Torres et al. | Polatuzumab vedotin combined with obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (G-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Preliminary results of a phase Ib/II dose-escalation study | |
| US20240166747A1 (en) | Antigen binding proteins and combinations thereof | |
| Deligne et al. | The vaccinal effect of monoclonal antibodies in cancer therapy |